Intermediate module molecule for activating chimeric antigen receptor effector cell and use thereof

By designing intermediate module molecules that target the specific binding of polypeptides to tumor-associated antigens, activate chimeric antigen receptor T cells, the problem of poor treatment results caused by antigen deletion and tumor heterogeneity is solved, and a variety of cancer tumors have been achieved Effective targeting and killing reduces cytotoxic side effects and promotes T cell infiltration.

WO2024240179A1PCT designated stage expired Publication Date: 2024-11-28ZHENGZHOU UNIV
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094676
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing chimeric antigen receptor T cells have antigen deletion or tumor heterogeneity when treating solid tumors, resulting in targeting failure, resulting in poor treatment effect, and may cause serious cytotoxic side effects, and are difficult to effectively infiltrate the tumor site. .

Method used

Develop an intermediate module molecule containing exogenous tag molecules and linkers that target polypeptides specifically bind to tumor-associated antigens for activation of chimeric antigen receptor effector cells, including CD44, EpCAM or GPC3 targeted polypeptides, binding specifically Sex antibodies or fragments thereof form a convertible chimeric antigen receptor T cell system to improve therapeutic efficacy.

Benefits of technology

By replacing the intermediate module molecules, it can effectively target mutated or lost antigens, improve the therapeutic effect of CAR-T cells, reduce cytotoxic side effects, enhance the therapeutic potential of various cancer tumors, and promote T cell infiltration and tumor cell killing .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094676_28112024_PF_FP_ABST
    Figure CN2024094676_28112024_PF_FP_ABST
Patent Text Reader

Abstract

An intermediate module molecule for activating a chimeric antigen receptor effector cell and the use thereof, belonging to the field of biomedicines. The present invention emphasizes researching and developing the intermediate module molecule which can regulate the activity of a chimeric antigen receptor T cell and regulate the interaction between the chimeric antigen receptor T cell and a target cell. The module molecule comprises: (a) a targeting polypeptide, which is a tumor target-binding polypeptide; (b) an exogenous tag molecule, capable of binding to the chimeric antigen receptor on the effector cell, and (c) a linker, linking the targeting polypeptide to the exogenous tag molecule. The effector cell is selected from a dendritic cell, a killer dendritic cell, a mast cell, a natural killer cell, a B lymphocyte, a T lymphocyte, a macrophage and precursor cells thereof.
Need to check novelty before this filing date? Find Prior Art

Description

An intermediate module molecule for activating chimeric antigen receptor effector cells and its application Technical Field

[0001] The present invention belongs to the field of biomedicine, and in particular relates to an intermediate module molecule for activating chimeric antigen receptor effector cells and applications thereof. Background Art

[0002] In recent years, the success of chimeric antigen receptor T (CAR-T) cells in treating leukemia and lymphoma has greatly bolstered researchers' confidence in CAR-T cell therapy. However, the majority of patients with solid tumors do not benefit from immunotherapy. Peritoneal dissemination is one of the most common features of advanced malignancies, often arising from primary tumors within the peritoneal cavity, such as gastric, colon, pancreatic, and ovarian cancers, or from intraperitoneal lymphomas. CAR-T therapy has made significant progress in preventing peritoneal dissemination, but many challenges remain to be overcome to expand its therapeutic scope. Lack of target antigen expression due to antigen loss or tumor heterogeneity renders CARs ineffective against many tumors. Some researchers have found that tumor evolution during treatment leads to loss of target expression and can contribute to resistance to CAR-T therapy. The application of existing CAR-T cells in solid tumors is limited by the inability to control activation and infiltration in vivo. For example, when chimeric antigen receptor T cells encounter the patient's antigen-positive cells, they proliferate rapidly, leading to severe symptoms caused by tumor lysis syndrome (TLS) and fatal cytokine release syndrome (CRS). Subsequent complications can also arise from persistent on-target activity of the chimeric antigen receptor T cells' antigens. For example, in the case of CART-19, the manipulated T cells kill not only malignant B cells but also indiscriminately kill normal B cells, leading to long-term B cell aplasia. Finally, the antigen specificity fixed in existing chimeric antigen receptor T cells precludes targeting antigen-loss escape mutants, which are the cause of relapse in 10% of all patients treated with CART-19, and solid tumors have difficulty achieving effective infiltration of conventional CAR-T cells, leading to resistance to CAR-T therapy.

[0003] Therefore, in order to improve the safety and practicality of chimeric antigen receptor T cells, there is an increasing demand for the development of intermediate modular molecular systems that can regulate the activity of chimeric antigen receptor T cells when severe cytotoxicity occurs and can convert the interaction between chimeric antigen receptor T cells and target cells when antigen mutation or loss occurs.

[0004] Summary of the Invention

[0005] One of the objectives of the present invention is to provide an intermediate module molecule for activating chimeric antigen receptor effector cells, wherein the intermediate module molecule comprises: (a) a targeting polypeptide, which is a tumor target binding polypeptide; (b) an exogenous tag molecule capable of binding to a chimeric antigen receptor on an effector cell, and (c) a linker that connects the targeting polypeptide to the exogenous tag molecule; the effector cell is selected from dendritic cells, cytotoxic dendritic cells, mast cells, natural killer cells, B lymphocytes, T lymphocytes, macrophages and their precursor cells.

[0006] Preferably, the targeting polypeptide is capable of specifically binding to CD44, EpCAM or GPC3 tumor-associated antigens.

[0007] More preferably, the amino acid sequence of the intermediate module molecule corresponding to CD44 is shown as SEQ ID NO.2; the amino acid sequence of the intermediate module molecule corresponding to EpCAM is shown as SEQ ID NO.8; and the amino acid sequence of the intermediate module molecule corresponding to GPC3 is shown as SEQ ID NO.10.

[0008] A second object of the present invention is to provide a composite system comprising: (a) the intermediate module molecule described above, and (b) a fusion protein, wherein the fusion protein is an antibody, an antigen-binding fragment of an antibody, a targeting binding polypeptide, or a chimeric antigen receptor comprising the same for targeting the intermediate module molecule.

[0009] Preferably, the antibody is a single-chain antibody, the nucleotide sequence of its heavy chain is shown in SEQ ID NO.2, the nucleotide sequence of the flexible peptide is shown in SEQ ID NO.3, and the nucleotide sequence of the light chain is shown in SEQ ID NO.4.

[0010] Preferably, the single-chain antibody nucleotide sequence (or its encoded amino acid sequence) has a nucleotide sequence with 80% or more homology with the sequence shown in SEQ ID NO: 1 (or its encoded amino acid sequence) (preferably at least 85%, 90%, 95%, 99% or 100% homology).

[0011] Preferably, the single-chain antibody heavy chain nucleotide sequence (or its encoded amino acid sequence) has a nucleotide sequence with 80% or more homology with the sequence shown in SEQ ID NO: 2 (or its encoded amino acid sequence) (preferably at least 85%, 90%, 95%, 99% or 100% homology).

[0012] Preferably, the single-chain antibody light chain nucleotide sequence (or its encoded amino acid sequence) has a nucleotide sequence with 80% or more homology with the sequence shown in SEQ ID NO: 4 (or its encoded amino acid sequence) (preferably at least 85%, 90%, 95%, 99% or 100% homology).

[0013] A third object of the present invention is to provide an effector cell, wherein the effector cell expresses the above-mentioned single-chain antibody.

[0014] A fourth object of the present invention is to provide the use of the above-mentioned intermediate module molecule in the preparation of a drug for improving the efficacy of chimeric antigen receptor T cells.

[0015] A fifth object of the present invention is to provide a preparation for improving the efficacy of chimeric antigen receptor T cells, wherein the preparation comprises the above-mentioned intermediate module molecule.

[0016] A sixth object of the present invention is to provide a drug for treating tumors, which comprises the above-mentioned preparation and effector cells.

[0017] A seventh object of the present invention is to provide the use of the above-mentioned effector cells or the above-mentioned intermediate module molecules in the preparation of drugs for treating tumors.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] When using the intermediate module molecules of the present invention, when an antigen mutates or for the treatment of multiple cancer tumors, the existing intermediate module molecules can be replaced with intermediate module molecules targeting new antigens generated by mutations, or intermediate module molecules targeting different tumor-associated antigens (TAAs) to more effectively treat cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 shows the structure and anti-tumor mode of SPAR CAR-T cells. A, The SPAR system consists of SPAR T cells and intermediate modular molecules called PTs. In the absence of PTs, SPAR T cells are inert. In the presence of PTs, SPAR T cells can form immune complexes by fusing a targeting peptide to a tag recognized by the antibody domain of SPAR. PTs are constructed from IgG antibodies that produce SCFV-based molecules. In this work, we developed a PT based on a tumor-targeting peptide. B, The structure of a switchable targeting peptide-mediated CAR-T cell (SPAR-T) and a targeting peptide tag (PT).

[0021] Figure 2 shows the binding and functional analysis of the CD44BP-Flag polypeptide (PT) on four peritoneally disseminated tumor cells, AsPC1, COLO205, SKOV3, and SNU1, as described in Example 1. Flow cytometry was used to detect CD44 expression on ASPC1, COLO205, SKOV3, and SNU1 cells using a CD44 antibody (A) and FITC-labeled CD44BP (B). C, Cell counting was used to assess the effect of CD44BP-Flag on the proliferation of ASPC1, COLO205, SKOV3, and SNU1 cells. Data shown are mean ± SD. Data are from three independent experiments, analyzed using a two-tailed paired t-test (ns, P > 0.05). D, Confocal microscopy was used to examine the stability of CD44BP-Flag on the tumor cell surface. Cells were stained with CD44BP-Flag-PT, and then the binding duration of the polypeptide PT on the tumor cell surface was measured using a FITC-labeled Flag antibody at different time points.

[0022] Figure 3 shows the results of the SPAR CAR-T system targeting and specifically lysing CD44-positive tumor cells in Example 2. A: The specific killing efficiency of the SPAR-T system in Skov3, Aspc1, SNU1, and Colo205 cells after 10 hours of treatment was determined using a lactate dehydrogenase (LDH) release assay. B: The effect of the SPART system administration sequence on cytotoxicity was determined using an LDH release assay with an E / T ratio of 10 for 10 hours. Elisa's method was used to measure INF-γ levels in different SPART system administration sequences. There are three modes of action: 100 nM / mL CD44BP-Flag, CAR-Flag, and SNU1 indicate simultaneous addition of SNU1; SNU1 and 100 nM / mL CD44BP-Flag are incubated before CAR-Flag T cells are added; and 100 nM / mL CD44BP-Flag and CAR-Flag T cells are incubated before SNU1 cells are added. C: A flow chart of the in vitro cytotoxicity of the SPAR-T system using CD44BP-Flag as the PT. Tumor cells (2×106 Cells) were implanted into NSG mice intraperitoneally and treated with Con-T cells, CAR-Flag cells, CD44BP-FlagPT or CD44BP-FlagPT in combination with CAR-Flag cells on day 14 after implantation. Then, for the next three days, mice in the experimental group were intraperitoneally injected with 1 mg / kg CD44BP-Flag every day, and the remaining three control group mice were intraperitoneally injected with PBS. D, In vivo imaging analysis of mice treated with different treatment strategies. Tumor growth curves were drawn using the average total photons. All data are expressed as Mean ± sd. Unpaired two-tailed t-test was used, ns>0.05, *p<0.05, **p<0.01.

[0023] Figure 4 illustrates the enhanced target cell lysis efficacy of the dual-PT SPAR CAR-T system in Example 3. A: Flow cytometry analysis of CD44 and EpCAM expression in SNU1 cells. B: SNU1 cells were incubated with SPAR-T cells in combination with single or dual PTs at specified E / T ratios for 10 hours. The in vitro cytotoxicity of different PTs on SPAR T cells was assessed using an LDH release assay. C: Flowchart of the in vitro cytotoxicity of the SPAR-T platform using single or dual PTs. Mice in the CD44BP-Flag and EpCAMBP-Flag groups were injected with 1 mg / kg PTs alternately for a total of four times, while mice in the dual PT group were injected with CD44BP-Flag and EpCAMBP-Flag alternately twice daily. D: Bioluminescence imaging was used to assess the in vivo cytotoxicity of SPART combined with single or dual PTs in mice. Tumor growth curves were plotted based on the mean total photon count. E: Survival analysis of mice with peritoneally disseminated SNU1 cells treated with single or dual PTs combined with SPART (n = 6).

[0024] Figure 5 shows the results of T cell infiltration and off-target effect analysis of the SPAR CAR-T system in Example 4. A: CD3 marker staining immunohistochemically detected T cell infiltration in tumor nodules. B: CD3+ T cells were randomly counted in 10 high-power fields (HPF) from each tumor section in each group (200×). C: INF-γ levels in serum of NSG mice at different time points after different treatment strategies (PBS, CAR-Flag, CAR-CD44FP-FLAGP-BP+EpCAMBP-FlaG). D: Antibody levels against CD44BP-Flag peptide in serum were measured by ELISA 14 days after a single immunization, 14 days after two immunizations, and 21 days after two immunizations. Serum was collected by centrifugation at 3000 rpm / min for 10 minutes at 4°C. E: Cytotoxicity of SPART and CD44BP-FlagPT against B16 mouse tumor cells. B16 cells were incubated with SPAR-T cells combined with CD44BP-FlagPT at the specified E / T ratios for 10 hours. F, Representative images of hematoxylin and eosin staining of mouse livers treated with different treatment strategies (PBS, CAR-Flag, CAR-Flag + CD44BP-Flag, CAR44BP + ED44BP-EpCAMBP-Flag) (scale bar, 50 μm). G, Serum ALT and AST levels in NSG mice transplanted with different strategies (PBS, CAR-Flag, CAR-Flag + CD44BP-Flag, CAR-Flag + CD44BP-Flag + EpCAMBP-Flag). ALT and AST were detected in triplicate, = 3 biologically independent groups. (Green squares indicate normal range values), Mean ± SD; unpaired, two-tailed t-test.

[0025] Figure 6 shows the cytotoxicity of the SPAR CAR-T system activated by the GPC3BP-Flag PT against SNU1 cells treated with dual-targeting therapy targeting CD44 and EpCAM in Example 5. A and B show the expression of CD44 and EpCAM on the surface of R-SNU1 (resistant SNU-1) cells using flow cytometry with fluorescently labeled CD44 or EpCAM antibodies. C shows the cytotoxicity of the SPAR CAR system against R-SNU1 cells using CD44BP-Flag and EpCAMBP-Flag as PTs. D shows a heat map of the top 200 membrane proteins analyzed in the RNA-Seq experiment. E and F show the positive rates of GPC3 in SNU1 cells (E) and R-SNU1 cells (F) detected by flow cytometry. G and H show the cytotoxicity of the SPAR CAR system combined with the GPC3 PT in R-SNU1 cells (G) and SNU1 cells (H). I and J, Metascape software was used to analyze the enrichment networks of increased genes (I) and decreased genes (fold change > 10) (J) in R-SNU1. DETAILED DESCRIPTION

[0026] Throughout this specification, unless otherwise defined, "%" used to express the concentration of a specific substance means (weight / weight)% for solid / solid, (weight / volume)% for solid / liquid, and (volume / volume)% for liquid / liquid. Chimeric antigen receptor T (CAR-T) cells express a single-chain antibody consisting of SEQ ID NOs. 2, 3, and 4 (i.e., SEQ ID NO. 1).

[0027] Example 1 Confirmation of tumor-associated antigen-specific binding of the intermediate modular molecule PT

[0028] The switchable penetrating peptide-mediated antigen receptor T cell therapy (SPAR-T) of the present invention uses a chimeric antigen receptor to target an exogenous small molecule tag antigen in an existing traditional chimeric antigen receptor system. The tag antigen and the tumor targeting peptide are connected by GGGGS as an intermediate module molecule (penetrating peptide-Flag, PT).

[0029] The present inventors conducted the following experiments to confirm whether the above-mentioned intermediate module molecule can be used as the intermediate acting module of the SPAR-T system.

[0030] It is well known that CD44 and its isoforms, such as alternatively spliced ​​v3-v10, are elevated in most cancers and correlate with cancer progression, making them potential diagnostic and therapeutic targets. Recently, Zhang Dan et al. identified a CD44-binding peptide (CD44BP) that selectively binds to CD44v3 and can be used for gastric cancer diagnosis. We used CD44 antibodies and FITC-labeled CD44BP (amino acid sequence shown in SEQ ID NO. 5) to detect CD44 expression in ASPC1, COLO205, SKOV3, and SNU1. As shown in Figures 2A and 2B, CD44BP detected CD44 on tumor cells at a similar rate as the CD44 antibody. We then evaluated the function and stability of CD44BP-PT (i.e., CD44BP-GGGGS-DDK, amino acid sequence shown in SEQ ID NO. 6). As shown in Figure 2C, CD44BP-PT had no effect on the proliferation of ASPC1, Colo205, Skov3, or Snu1. Furthermore, when cells incubated with CD44 PT were stained with FITC-Flag antibody, the peptide was detected to remain on the cell surface for more than 8 h ( Figure 2D ), indicating that these fused peptides could still be used for further SPAR-T cell therapy.

[0031] Example 2 Lysis of CD44-positive tumor cells by retargeting SPAR-T cells in a PT-dependent and target-specific manner

[0032] To validate the cytotoxicity of the SPAR-T system, the inventors constructed a conventional CAR-T containing a Flag single-chain antibody (nucleotide sequence shown in SEQ ID NO. 1) and synthesized CD44BP-Flag PT (Figure 1B). LDH cytotoxicity assays demonstrated that the SPAR-T system exhibited cytotoxicity against ASPC1, SKOV3, Colo205, and SNU1 tumor cells in the presence of CD44BP PT (100 nM / mL). The cytotoxicity of SPAR-T cells was dependent on the effector cell to target cell (E:T) ratio (Figure 3A). Neither control T cells, SPAR-T cells without PT, nor PT alone induced tumor cell lysis (Figure 3A). Our data also demonstrated that the SNU1 cell line, which expresses low levels of CD44 (Figure 2A), was less sensitive to cytotoxicity induced by SPAR-DDKT cells. Of note, we examined the effect of changing the incubation order of system components (tumor cells, SPAR-T cells, PT (CD44BP)) to determine whether the efficacy depends on the order of administration of the components (CD44BP-Flag+CAR-Flag+SNU1 means that CD44BP-Flag, CAR-Flag, and SNU1 were added simultaneously. SNU1+CD44BP-Flag armed CAR-Flag means that CAR-Flag T cells were incubated with 100 nM / mL CD44BP-Flag for 40 min, washed with PBS, and then injected with SNU1 cells. CD44BP-Flag armed SNU1+CAR-Flag means that SNU1 cells were incubated with 100 nM / mL CD44BP-Flag, incubated at 37°C for 40 min, washed with PBS, and then injected with CAR-Flag). T cells were added to the wells). As shown in Figure 3B, changing the order of administration had no effect on the cytotoxicity of the treatment, and the IFN-γ level also confirmed this result (Figure 3B). The effect of peptide-mediated SPAR-T on tumor clearance was then tested in vivo. ASPC1 (pancreatic cancer), SKOV3 (ovary), COLO205 (colorectal) and SNU1 (stomach) were intraperitoneally implanted into NSG mice. After 14 days, the tumors grew to 10 10 The treatment cycle started when the photon counts were 0.01 (each model was divided into Control T (unmodified T cells) and Treatment Control Group (injected with 100ul PBS liquid containing 2×10 7 T cells / 100 μL), CAR-Flag T peptide-free treatment group (100 μl PBS liquid, containing 2×107 T cells / 100 μL), CD44BP-flag peptide (i.e., CD44BP-PT) alone treatment group (injection of 100 ul PBS liquid containing 100 μg / 100 μL of CD44BP-PT), CAR-flag T+CD44BP-flag peptide treatment group (injection dose and concentration were the same as those of the CAR-Flag T no peptide treatment group and the CD44BP-flag peptide alone treatment group). Among them, (1) the above four groups were injected once on the 14th day after tumor inoculation, and the Control T (unmodified T cells) treatment control group and the CAR-Flag T peptide-free treatment group were injected only once; (2) After the first injection of the CD44BP-flag peptide alone treatment group, the same dose of CD44BP-Flag peptide was injected into the peritoneal cavity (100μg / 100μL) once a day for 3 consecutive days; (3) In the CAR-flag T+CD44BP-flag peptide treatment group, CAR-Flag T cells (100ul PBS liquid containing 2×10 7 The researchers administered a mixture of 100 T cells / 100 μL (100 μg / 100 μL) and CD44BP-Flag (100 μg / 100 μL of CD44BP-PT in 100 μL of PBS), followed by daily intraperitoneal injections of the same concentration and dose of CD44BP-Flag peptide for three consecutive days (Figure 3C). As shown in Figure 3D, all four models demonstrated therapeutic efficacy, demonstrating the anti-tumor potential of this therapeutic intervention. As observed in vitro, the SNU1 model, which exhibits lower cell surface CD44 expression, showed less promising results compared to the other three groups.

[0033] Example 3 Dual PT-directed SPAR-T enhances tumor cell lysis

[0034] Because low CD44 expression in SNU1 cells could explain the low cytolytic activity, the inventors tested an EpCAM-targeting peptide (amino acid sequence shown in SEQ ID NO. 7). As shown in Figure 4A, EpCAM combined with CD44BP detected 96% of SNU1 cells. The inventors hypothesized that the SPAR-T system would exhibit greater therapeutic efficacy in vivo if both PTs were used simultaneously in the treatment regimen. The inventors synthesized EpCAMBP-Flag (shown in SEQ ID NO. 8). In vitro LDH release assays (LDH detection kit, Tongren Chemical) demonstrated that SPAR-T combined with dual PTs (final concentration of each PT: 100 nM / ml) exhibited greater cytotoxicity against SNU1 cells compared to the single PT group (Figure 4B). As previously described, these findings were further validated using the orthotopic SNU1-Luc model (Figures 4C and 4D). Compared to single PT treatment, dual PT treatment significantly improved antitumor efficacy (Figure 4E) and overall survival (Figure 4E).

[0035] Example 4 Penetration and off-target effects of the SPART system

[0036] It is well known that T cell infiltration is crucial for CAR-T therapy of solid tumors. The present inventors examined T cell infiltration within peritoneal disseminated tumors after treatment. As shown in Figures 5A and 5B, 48 hours after SPAR-T system treatment, T cell infiltration in the PT-treated group was significantly superior to that in the untreated group. However, no significant difference was observed after 166 hours of SPAR-T cell treatment. This suggests that PTs play a role in promoting T cell infiltration. ELISA assays confirmed elevated INF-γ levels in the serum of NSG mice treated with SPAR-T containing PTs (Figure 5C), demonstrating the system's potent tumor cell-killing ability. Antibodies are typically large in molecular weight, and immunogenicity concerns are one of the reasons we chose not to use them as PTs. The present inventors examined anti-CD44BP-Flag antibody levels in the serum of BalB / c mice immunized with CD44BP-Flag, and found no significant increase in antibody levels compared to the PBS-immunized group (Figure 5D). Traditional CAR-T therapy carries numerous risks and limited efficacy, with the most common side effects including off-target toxicity, allergic reactions, and tumor lysis syndrome (TLS). Our data showed that CD44BP has a strong binding affinity for mouse B16 melanoma cells. Since SPAR-T using CD44BP-FlagPT was able to kill B16 cells (Figure 5E), we used this cell line to further evaluate the off-target effects of the SPAR-T system. The SPART system can kill mouse B16 melanoma cells, so when PT can bind, it can also kill abdominal cells in NSG mice. However, HE staining showed that our SPAR system had no significant toxicity to mouse livers (Figure 5F), and this hypothesis was further verified by measuring serum ALT and AST levels (Figure 5G). The inventors' experiments above are intended to demonstrate the safety and efficacy of the SPAR-T system.

[0037] Example 5: The SPAR-T system can be an effective strategy to overcome CAR-T tolerance

[0038] The inventors demonstrated in animal studies that administration of dual PTs enhanced antitumor activity, but this treatment still did not completely eliminate SNU1 cells. We isolated and cultured SNU1 cells that were not killed by the dual PT SPAR-T system (referred to as R-SNU1 cells). We found that expression of CD44 and EpCAM was nearly lost (Figures 6A and 6B). As expected, the SPAR-T platform, using CD44BP and EpCAM-binding peptide (EpCAMBP) as PTs, showed no in vitro cytotoxicity against R-SNU1 cells (Figure 6C). To further explore its potential mechanism of action and other therapeutic targets, we performed RNA sequencing on R-SNU1 and SNU1 cells. Analysis of the RNA-Seq results (Figure 6D) revealed a series of changes in membrane proteins: expression of two targets, CD44 and EpCAM, decreased, while expression of other membrane proteins increased. These genes, such as GPC3, could serve as targets for PTs. Flow cytometry results showed that 73% of R-SNU1 cells were GPC3-positive (Figures 6E and 6F), and this expression was enriched after treatment with the dual-PTSPARCAR system, CD44BP-Flag and EpCAMBP-Flag. We introduced GPC3BP-Flag (amino acid sequence shown in SEQ ID NO. 10) as a PT to test the cytotoxicity of SPARCAR-T cells in SNU1 and R-SNU1 cells (Figures 6G and 6H). As expected, the primary cause of resistance to SPAR-T therapy appears to be escape, caused by the inability of SPAR-T cells to effectively target all tumor cells. Therefore, it is important to screen for penetrating peptides that specifically target tumor cells at different stages of treatment. Furthermore, the remaining cells after combined CD44PT and EpCAMPT treatment with SPAR-T lost a range of membrane proteins, resulting in several changes in cell properties (Figures 6I and 6J). For example, mesenchymal-epithelial transition (MET) leads to reduced tumor cell migration and increased adhesion, which reduces the contact area with SPAR-T cells and may result in reduced cytotoxicity.

[0039] Nucleic acid sequence 1 (SEQ ID NO. 1):

[0040] Nucleic acid sequence 2 (SEQ ID NO. 2):

[0041] Flag SCFV H chain

[0042] Nucleic acid sequence 3 (SEQ ID NO.3):

[0043] Flexible peptide sequence

[0044] Nucleic acid sequence 4 (SEQ ID NO.4):

[0045] Flag SCFV L chain

[0046] Amino acid sequence

[0047] Amino acid sequence 1 (SEQ ID NO.5):

[0048] CD44BP:WHPWSYLWTQQA.

[0049] Amino acid sequence 2 (SEQ ID NO.6):

[0050] CD44BP-Flag:WHPWSYLWTQQAGGGGSDYKDDDDK.

[0051] Amino acid sequence 3 (SEQ ID NO.7):

[0052] EpCAMBP:KHLQCVRNICWS.

[0053] Amino acid sequence 4 (SEQ ID NO.8):

[0054] EpCAMBP-Flag:KHLQCVRNICWSGGGGSDYKDDDDK.

[0055] Amino acid sequence 5 (SEQ ID NO.9):

[0056] GPC3BP:SNDRPPNILQKR.

[0057] Amino acid sequence 6 (SEQ ID NO.10):

[0058] GPC3BP-Flag:SNDRPPNILQKRGGGGGSDYKDDDDK.

[0059] Amino acid sequence 7 (SEQ ID NO.11):

[0060] Linker:GGGGS.

[0061] The embodiments described above are merely descriptions of preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Without departing from the spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by persons skilled in the art should fall within the scope of protection defined by the claims of the present invention.

Claims

1. An intermediate module molecule for activating chimeric antigen receptor effector cells, It is characterized in that The intermediate module molecule comprises: (a) a targeting polypeptide, which is a tumor target binding polypeptide; (b) an exogenous tag molecule, which can bind to a chimeric antigen receptor on an effector cell, and (c) a linker that connects the targeting polypeptide to the exogenous tag molecule; the effector cell is selected from dendritic cells, cytotoxic dendritic cells, mast cells, natural killer cells, B lymphocytes, T lymphocytes, macrophages and their precursor cells.

2. The intermediate module molecule according to claim 1, It is characterized in that The targeting polypeptide can specifically bind to CD44, EpCAM or GPC3 tumor-associated antigens.

3. The intermediate module molecule according to claim 2, It is characterized in that The amino acid sequence of the intermediate module molecule corresponding to CD44 is shown in SEQ ID NO.2; the amino acid sequence of the intermediate module molecule corresponding to EpCAM is shown in SEQ ID NO.8; and the amino acid sequence of the intermediate module molecule corresponding to GPC3 is shown in SEQ ID NO.

10.

4. A composite system, It is characterized in that The composite system comprises: (a) the intermediate module molecule according to any one of claims 1 to 3, and (b) a fusion protein, wherein the fusion protein is an antibody, an antigen-binding fragment of an antibody, a targeting binding polypeptide, or a chimeric antigen receptor comprising the same for targeting the intermediate module molecule.

5. The composite system according to claim 4, It is characterized in that The antibody is a single-chain antibody, the nucleotide sequence of its heavy chain is shown in SEQ ID NO.2, the nucleotide sequence of the flexible peptide is shown in SEQ ID NO.3, and the nucleotide sequence of the light chain is shown in SEQ ID NO.

4.

6. an effector cell, It is characterized in that The effector cells express the single-chain antibody of claim 4.

7. Use of the intermediate module molecule according to any one of claims 1 to 3 in the preparation of a drug for improving the efficacy of chimeric antigen receptor T cells.

8. A preparation for improving the efficacy of chimeric antigen receptor T cells, It is characterized in that The formulation comprises the intermediate modular molecule according to any one of claims 1-3.

9. A drug for treating tumors, It is characterized in that The medicament comprises the preparation described in claim 8 and the effector cell described in claim 6.

10. Use of the effector cell according to claim 6 or the intermediate module molecule according to any one of claims 1 to 3 in the preparation of a drug for treating tumors.

Citation Information

Patent Citations

  • CD44 targeting polypeptide and application thereof for preparing affinitive probe used for screening early gastric cancer

    CN104327161A

  • Preparation method of natural ligand-mediated multi-target recognition regulatable genetically engineered immune cell

    CN111454909A

  • Vector containing double-target chimeric antigen receptor gene, CAR-T cell and application of CAR-T cell

    CN111560075A

  • Switch molecule and switchable chimeric antigen receptor

    CN111989342A

  • Chimeric antigen receptor mononuclear / macrophage targeting GPC3 as well as construction method and application of chimeric antigen receptor mononuclear / macrophage

    CN115772232A